Market Place
Sourcing Support
Portage Biotech Reports Fiscal Year Results Ending March 31, 2025
25 Jul 2025 //
GLOBENEWSWIRE
Portage Biotech Regains Nasdaq Compliance
25 Jun 2025 //
GLOBENEWSWIRE
Portage Biotech and Compedica Stock-for-Stock Exchange
09 Jun 2025 //
GLOBENEWSWIRE
Portage Confirms Preclinical PORT-7 Results in Mesothelioma
28 Apr 2025 //
GLOBENEWSWIRE
Portage Bio Reports Promising Preclinical Results In Mesothelioma
27 Mar 2025 //
GLOBENEWSWIRE
Portage Resumes Enrollment In Final Cohort Of ADPORT-601 Ph1
12 Mar 2025 //
GLOBENEWSWIRE
Portage Biotech Resumes Dose Escalation for Port-6 in ADPORT-601
12 Mar 2025 //
GLOBENEWSWIRE
Portage Biotech Gets Extension for Stock Exchange Compliance
12 Feb 2025 //
GLOBENEWSWIRE
Portage Biotech Announces Completion of $2.15 M Private Financing
30 Jan 2025 //
GLOBENEWSWIRE
Portage launches Tarus` solid tumor portfolio into new offshoot
06 Jan 2025 //
FIERCE BIOTECH
Portage Biotech Relaunches Adenosine Unit, Names Peter Molloy CEO
06 Jan 2025 //
GLOBENEWSWIRE
Portage finds hope in sale of iNKT agonists to Immunova
17 Dec 2024 //
FIERCE BIOTECH
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
12 Dec 2024 //
GLOBENEWSWIRE
Portage Biotech Reports Results for Fiscal Quarter Ended Sept 30
26 Nov 2024 //
GLOBENEWSWIRE
Portage Biotech Reports Fiscal Quarter Results And Business Update
27 Aug 2024 //
GLOBENEWSWIRE
Portage Biotech Reports FY-End 2024 Results And Business Update
15 Aug 2024 //
GLOBENEWSWIRE
Portage Biotech Announces 1-for-20 Reverse Stock Split
13 Aug 2024 //
GLOBENEWSWIRE
Portage Biotech To Expand Strategic Alternatives Evaluation
12 Apr 2024 //
GLOBENEWSWIRE
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
26 Mar 2024 //
GLOBENEWSWIRE
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023
28 Feb 2024 //
GLOBENEWSWIRE
Portage Biotech Reports Business and Strategic Update
04 Jan 2024 //
GLOBENEWSWIRE
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023
28 Nov 2023 //
GLOBENEWSWIRE
Portage Biotech Presents Updates on its iNKT and Adenosine programs
06 Nov 2023 //
GLOBENEWSWIRE
Portage Biotech Announces $6.0 Million Registered Direct Offering
29 Sep 2023 //
GLOBENEWSWIRE
Portage Biotech Announces Collaboration with Merck to Evaluate Adenosine
05 Sep 2023 //
GLOBENEWSWIRE
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023
30 Aug 2023 //
GLOBENEWSWIRE
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6
26 Jun 2023 //
GLOBENEWSWIRE
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2
05 Jun 2023 //
GLOBENEWSWIRE
Portage Biotech to Participate in Panel Discussion During 2023 BIO Conference
01 Jun 2023 //
GLOBENEWSWIRE
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
Portage Biotech to Present at Oppenheimer Annual Healthcare Conference
07 Mar 2023 //
GLOBENEWSWIRE
Portage Biotech to Participate in Citi`s 2023 Virtual Oncology Leadership Summit
15 Feb 2023 //
GLOBENEWSWIRE
